Abstract: A measure that can readily prevent arthropod-borne diseases such as malaria that are contracted by 3 to 5 hundred million people worldwide yearly and that cause death of as many as 1.5 to 2.7 million people. By spraying in advance on the skin an arthropod-borne disease preventive agent or the like including chlorine dioxide as an effective component thereof, it is possible to provide repelling effect against arthropods such as infected mosquitoes that bear malaria protozoa and also to prevent biting of the skin by the arthropod, thus reducing contraction of the arthropod-borne diseases.

Abstract: A surgical system for small-pit closure in hollow organs is provided. The surgical system is provided with a surgical device for small-pit closure in hollow organs, with the surgical device including the following components: a suture-member cartridge in which a pair of parallel tubular members that accommodate respective suture members are feedably connected to the rear ends of a pair of arrow-shaped members that latch into tissue in a hollow organ; an auxiliary shooting unit having plungers respectively provided in a pair of cylinders open at both ends; a hollow-organ-insertable unit configured of a pair of flexible air tubes; and a gas shooter that sequentially discharges compressed air or high-pressure gas into the open-ended cylinders in response to operations of a trigger, for sequentially ejecting the arrow-shaped members and driving the same into tissue in the hollow organ on both sides of a small pit site.

Abstract: A recombinant transfer vector capable of expressing a foreign gene fused to a viral gene under the control of dual promoters and a recombinant baculovirus, and methods for production thereof, as well as pharmaceuticals comprising the recombinant baculovirus as an active ingredient.

Abstract: Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) positive for ALK mutations are likely to respond to treatment with an ALK inhibitor and/or whether a patient having such cancer(s) is likely to have a relatively slower disease progression. Further described are methods for prognosing a time course of disease in a subject having such cancer.

Abstract: A cardiovascular risk evaluation apparatus includes a hypoxic acquisition unit for acquiring a measurement result that includes a blood oxygen saturation level measured in a hypoxic period in which the blood oxygen saturation level of a subject is lower than a threshold value, and a blood pressure measured when the blood oxygen saturation level was measured; a non-hypoxic acquisition unit for acquiring a measurement result that includes a blood oxygen saturation level measured in a non-hypoxic period of the blood oxygen saturation level of the subject, and a blood pressure measured when the blood oxygen saturation level was measured; and an indicator acquisition unit for acquiring a cardiovascular risk evaluation indicator for the subject based on the relationship between blood oxygen saturation level and blood pressure, which is based on the measurement results acquired by the hypoxic acquisition unit and the non-hypoxic acquisition unit.

Abstract: A blood pressure measurement apparatus for measuring blood pressure in a predetermined period includes a blood pressure measuring unit for measuring the blood pressure of a subject, an information acquiring unit for acquiring information that is related to variation in blood pressure and changes in a time-series in the predetermined period, a determining unit for determining whether or not the information acquired by the information acquiring unit satisfies a predetermined condition, and a trigger output unit for, in a case where the determining unit determines that the predetermined condition is satisfied, causing the blood pressure measuring unit to start and execute blood pressure measurement. The predetermined condition is expressed as a function of time that varies and is measured in the predetermined period.

Abstract: The present invention provides a method for evaluating preservative effect of a tissue preservation solution, comprising immersing a mammalian tissue introduced with a luminescence or fluorescence labeling gene in the tissue preservation solution, measuring a luminescence or fluorescence level by the labeling gene in the tissue after immersion, and evaluating the preservative effect of the tissue preservation solution based on the luminescence or fluorescence level.

Abstract: A cardiovascular risk evaluation apparatus includes a hypoxic acquisition unit for acquiring a measurement result that includes a blood oxygen saturation level measured in a hypoxic period in which the blood oxygen saturation level of a subject is lower than a threshold value, and a blood pressure measured when the blood oxygen saturation level was measured; a non-hypoxic acquisition unit for acquiring a measurement result that includes a blood oxygen saturation level measured in a non-hypoxic period of the blood oxygen saturation level of the subject, and a blood pressure measured when the blood oxygen saturation level was measured; and an indicator acquisition unit for acquiring a cardiovascular risk evaluation indicator for the subject based on the relationship between blood oxygen saturation level and blood pressure, which is based on the measurement results acquired by the hypoxic acquisition unit and the non-hypoxic acquisition unit.

Abstract: A blood pressure measurement apparatus for measuring blood pressure in a predetermined period includes a blood pressure measuring unit for measuring the blood pressure of a subject, an information acquiring unit for acquiring information that is related to variation in blood pressure and changes in a time-series in the predetermined period, a determining unit for determining whether or not the information acquired by the information acquiring unit satisfies a predetermined condition, and a trigger output unit for, in a case where the determining unit determines that the predetermined condition is satisfied, causing the blood pressure measuring unit to start and execute blood pressure measurement. The predetermined condition is expressed as a function of time that varies and is measured in the predetermined period.

Abstract: A system and method for use in NOTES is provided for reducing surgical invasiveness. An insertion body that is connected by an anvil assembly and joined to a thin wire guide or electric guide wire, is inserted via a natural orifice into a hollow organ so as to incise and remove a diseased or defective site from the hollow organ by using a pair of or front-end/rear-end linear cutters of a linear cutting/stapling device or linear stapler, after which the two cut ends of the tract are anastomosed and recovered by a circular anastomosis surgical stapler that is provided with the system.

Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.

Abstract: [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. [Means for Solution]According to one embodiment of the present invention, a method for testing angiitis which includes a step of detecting an antibody specifically recognizing a moesin in a biological sample is provided. In addition, according to another embodiment of the present invention, a reagent for testing angiitis which contains a substance that detects an antibody specifically recognizing a moesin in a biological sample is provided.

Abstract: The present invention provides a means for transferring a therapeutic gene of interest into a nervous system cell by a highly-efficient and simpler means. More specifically, the present invention provides a recombinant vector that uses an adeno-associated virus (AAV), a method for manufacturing the recombinant vector, and a method for using the recombinant vector. More specifically, recombinant adeno-associated virus virions, which are capable of passing through the brain-brain barrier, for transferring a therapeutic genes of interest into a nervous system cell in a highly-efficient manner, a drug composition containing the recombinant adeno-associated virus virions, a method for manufacturing the recombinant adeno-associated virus virions, and a kit or the like are provided.

Abstract: The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example.

Abstract: Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.

Abstract: A treatment instrument for an endoscope includes: an operation portion; a cylindrical sheath that is connected to the operation portion and that also comprises an insertion portion; an axial electrode that is protruded from and retracted into a distal end opening portion of the sheath by an operation of the operation portion; and a distal end electrode portion that is provided at a distal end portion of the axial electrode; wherein a tapered portion is formed at a distal end portion of the sheath, the tapered portion being in a tapered shape that a distal end side of the distal end portion is narrower than a proximal end side of the distal end portion.

Abstract: The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.

Abstract: The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1; (b) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (a) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and (d) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (c) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity, as an active component.

Abstract: The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example.

Abstract: The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example.